GlassScriptPhysician profile
Susana Campos
NPI 1912966052
$227,450.86
in general payments reported to CMS, 2019-2025
19 companies · $56K in 2025
The $56K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $15K · 2021: $30K · 2022: $42K · 2023: $18K · 2024: $42K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $87K · Travel and Lodging: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,850 · Food and Beverage: $1,666 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $208 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $86,699.86 |
| Travel and Lodging | $19,811.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,850.00 |
| Food and Beverage | $1,666.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $208.31 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45,997.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $41,356.70 | 2021-2025 | Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $31,592.13 | 2020-2025 | Jemperli, Zejula |
| Genmab U.S., INC. | $25,742.29 | 2024-2025 | Epkinly, Tivdak |
| Merck Healthcare Kgaa | $17,066.50 | 2025 | |
| Merck Sharp & Dohme LLC | $15,395.00 | 2021-2024 | |
| Immunogen, INC. | $10,687.02 | 2023-2024 | Elahere, Elahere |
| Pfizer INC. | $9,409.43 | 2024 | |
| Emd Serono Research & Development Institute, INC. | $8,172.36 | 2025 | |
| Seagen INC. | $5,160.44 | 2020-2022 | |
| Tesaro, INC. | $4,333.67 | 2019 | |
| Abbvie INC. | $2,980.96 | 2025 | |
| Emd Serono, INC. | $2,700.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,292.50 | 2021 | |
| Clovis Oncology, INC. | $1,669.62 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,290.00 | 2023 | |
| Corcept Therapeutics | $776.22 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $650.00 | 2021 | |
| Taiho Oncology, INC. | $178.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susana Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.